Quitting Strategies + Varenicline for Smoking Cessation
Trial Summary
What is the purpose of this trial?
The purpose of this research study is to understand whether concurrent treatment for cigarettes and e-cigarettes in which an individual quits both products at the same time (QUIT-C) or sequential treatment in which an individual quits cigarettes first followed by e-cigarettes is more effective for quitting both products. The study will also compare the effect of treatment on health-related biomarkers. All participants will receive varenicline, a medication used to treat tobacco use dependence, counseling, and cessation resources (i.e., links to text-based support, self-change booklet). Varenicline helps to reduce cravings for tobacco use and decreases the pleasurable effects of cigarettes and other tobacco products.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using any smoking cessation services or FDA-approved smoking cessation medications.
What data supports the effectiveness of this treatment for smoking cessation?
Research shows that combining varenicline (a medication to help quit smoking) with counseling can significantly improve quit rates. In one study, at least 44% of patients successfully quit smoking after 12 weeks of varenicline treatment, and other studies found that adding counseling to varenicline further increased the chances of quitting.12345
Is varenicline safe for smoking cessation?
Varenicline, also known as Chantix, has been linked to some safety concerns, including possible neuropsychiatric side effects (mental health-related issues), seizures, and interactions with alcohol. There are also reports of adverse cardiovascular events (heart-related issues) associated with its use. It's important to discuss these risks with a healthcare provider before starting treatment.678910
How is the drug varenicline unique for smoking cessation?
Varenicline is unique because it works by partially activating the same receptors in the brain that nicotine does, which helps reduce withdrawal symptoms and cravings while also making smoking less satisfying. This mechanism is different from other treatments like nicotine replacement therapy or bupropion, and it has been shown to be more effective in helping people quit smoking.1371112
Eligibility Criteria
This trial is for adults who have been smoking cigarettes and using e-cigarettes for at least 3 months, smoke 5+ cigarettes daily, use e-cigarettes on most days, and are ready to quit both within a month. It's not for pregnant or breastfeeding women, those unable to consent, people with severe kidney issues or unstable heart conditions, or users of other tobacco products more than once a week.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 12 weeks of varenicline, weekly individual counseling, and access to cessation resources for either concurrent or sequential cessation of cigarettes and e-cigarettes
Follow-up
Participants are monitored for cigarette and e-cigarette abstinence and health-related biomarkers
Treatment Details
Interventions
- Counseling (Behavioral Intervention)
- Guided Self-Change Booklets (Behavioral Intervention)
- Varenicline (Anti-smoking Medication)